One funded PhD studentship is available within the University of Kent's Centre for BioMedical Informatics [1]. The studentship will cover tuition fees for UK or EU students, and a maintenance bursary (currently at £13,300 per year). The award will be for full-time study starting in September 2010, and will continue for three years subject to satisfactory progress. In addition to working on a chosen PhD research project, the successful student will be required to spend 6 hours per week during the University term time teaching and demonstrating. Applications from non-EU students are invited, but the student would have to fund the difference between EU fees and overseas fees themselves if their application was successful.

A list of projects is given below. All of these projects reflect the interdisciplinary aims of the Centre, which promotes links and joint projects between the various disciplines in the Faculty. These projects are based at the Canterbury Campus,

Qualifications

Applicants should have a 1st, 2:1 or a Masters degree (or overseas equivalent) in a subject of relevance to the project being applied for.

How to apply

  1. Please use the online form [2].
  2. Choose Computer Science as the discipline of study.
  3. Under the section for proposed research, please begin with the sentence "I am applying for the CBMI studentship and I am interested in the project projectname".
  4. Please use the space in the research proposal section to indicate interest and qualifications.

Restrictions

  1. Applicants may apply for only one project.

Terms and Conditions

Applicants will automatically be considered for other studentships offered by the University in that project area. We would be interested to hear from self-funding students in these areas - please email [log in to unmask]  or [log in to unmask].

Please contact the named supervisors with specific queries about the projects

 

 

 

·         Analysis and processing of Optical Coherence Tomography images for the recognition of eyelid cancer

Supervisors: Prof. Adrian Podoleanu  (School of Physical Sciences; [log in to unmask] ), Dr. Ali Hojjatoleslami  (Biosciences; [log in to unmask] )

Optical Coherence Tomography is a new high resolution optical imaging that has become a popular diagnostic tool in ophthalmology, and skin cancer detection. The clinical application of OCT is rapidly evolving as recent studies demonstrate that this versatile imaging technology can be used in the clinic to improve the diagnosis of life-threatening diseases in their early stage [1-5]. It is shown that OCT images of lesions can be used to detect specific cancer tissue from surrounding normal tissue. One of the life threatening disease is eyelid cancer which non-invasive OCT imaging can help the specialists to diagnose the patient in its early stage of development. Our initial study of eyelid cancer images illustrate that the pathological signs can be traced on OCT images suggesting that image processing techniques can be used to detect the cancerous tissue.

This project focuses on the design of an automatic algorithm for the detection of eyelid cancer from OCT images by applying image computing techniques for image enhancement, the detection of suspected tissue, and the categorization of the tissue to cancerous and non-cancerous tissue. OCT images suffer from poor contrast and high level of speckle noise.

A set of OCT images of eyelid cancer with pathological images and clinical data, which is obtained by Adrian Podoleanu's group, will be used for this project. The programme involves the following steps:

 

This interdisciplinary project is suitable for a graduate with image processing, or a closely related discipline with strong programming skills and interest in the applications of computing in biomedical science. Experience on medical image analysis applications is an advantage. The student will join an interdisciplinary team and be supervised jointly by the Neurosciences and Medical Image Computing group of Biosciences and Applied Optics Group in the School of Physical Sciences. There will also be collaboration with Dermatology and Pathology departments of Maidstone and Tunbridge Wells NHS Hospital Trust.

M. Avanaki, S. Hojjatoleslami and A. Podoleanu, "Investigation of computer- based skin cancer detection using optical coherence tomography," Journal of Modern Optics, vol. 56, pp. 1536-1544, 2009.

C. Ahlers, U. Schmidt-Erfurth, Three-dimensional high resolution OCT imaging of macular pathology, Optics Express, Vol. 17, Iss. 5, pp. 4037- 4045, March 2009.

Julia Welzel, Optical coherence tomography in dermatology: a review, Skin Research and Technology, Volume 7 Issue 1, Pages 1-9, Jul 2008.

Lingley-Papadopoulos, Colleen A., Image analysis of Optical Coherence Tomography images of the urinary bladder for the recognition of bladder cancer, Dissertation, Biomedical Engineering, The George Washington University, June 2009.

Vrushali Raj Korde , Optical Imaging Modalities: From Design to Diagnosis of Skin Cancer, PhD thesis, University of Arizona, January 2009.
B. Rakesh Penmetsa, OCT imaging for eyelid cancer detection, MSc Thesis, School of Physical Sciences, University of Kent, UK, 2008.

 

·         Methods for the detection of Drug Effects using EEG Data

Supervisors: Prof. Phil Brown  (School of Mathematics, Statistics and Actuarial Science;[log in to unmask] ) and Dr. Ali Hojjatoleslami  (Neuroscience and Medical Image Computing  Group; [log in to unmask] )

Summary. Many potential drug targets are localised within the central nervous system (CNS) and it is therefore critical to understand if, and to what degree, the drug crosses the blood/brain barrier. However the key problem with central drug targets is that we cannot directly monitor drug levels in the brain, so indirect methods are required. One method is to measure the general activity of the brain via scalp electrodes (the so called electroencephalogram (EEG)). The EEG is normally used to study proconvulsant activity or to study sleep changes. "Snap shot" signatures in rats have been noted by Dimpfel (2003), but these are not time-varying, but other work has shown that the EEG signal contains a "signature" which can be used to directly measure the activity of drug in the brain over time.

Pfizer's current studies use a telemetrised Rat model, which yield a single-channel EEG signal, and data of this form will be available for the student to develop analysis and detection methods. They may also be able to access to EEG data from human subjects, which is more complex, with signal from multiple channels. If they have access to this data the student will be able to extend the methods used for the simpler rat EEG signals to the more complex human case. (See Saletu et al (2002) for previous work in this area).

The student will be working in a novel area needing primary statistical/signal analysis skills, and will gain experience in the understanding of electrophysiological measurements, and analysing EEG signal. The analysis skills developed and learned in the analysis of EEG data will be applicable to other high dimensional data problems. The analysis of high dimensional data is increasingly important, and poses a wide range of interesting questions.

Non-invasive biological markers of brain activity such as EEG data are important in the drug discovery process, and the student should be able to make a valuable contribution to improving these processes. The methods being developed are also translatable, as they can be used on both animal and man.

Aim EEG signals will change depending on the status of the animal/human, as brain-wave patterns change markedly during deep sleep, sleep, active state, and resting. In rats, in particular, transition between the different states can occur many times during a typical 12 hour study. For a given drug type we are looking for a "signature"(a profile across frequencies) in the EEG signal which is independent of the sleep state. The amount of this profile present in a given spectrum at a given time will reflect the affect of the drug present in the brain. We expect these signals to follow a PK/PD model, but may not necessarily know the exact parameters, so these will need to be estimated as part of the signature detection.

Detecting this signature could provide an important biomarker for the drug discovery and development process. It will provide a non-invasive way of detecting drug effects that is translatable, so can be used in both animal and human studies.

Possible Analysis Methods. The data format takes the form of a matrix or a three dimensional array, so multivariate methods are expected to be useful (a relevant approach to the three dimensional case is Linder and Sundberg, 2002, and references therein). Pfizer's current approach uses a modified version of Canonical Correlation Analysis (MDCCA). A novel part of the study is that we have a functional form for the response we are trying to detect, so methods which are capable of detecting this underlying functional form and quantifying it (eg Ramsay and Silverman, 1997) will also be relevant. The MDCCA simply optimises the correlation across time between a linear combination of the power spectrum and the standard PK/PD curve parameterised according dose level. There are questions of robustness, alternatives to the simple two compartment PK/PD model, diagnostics for detecting inadequacies in the model and overall inferential properties both classical and Bayesian.

This project will be partially supported by one of the world's leading pharmaceutical companies, Pfizer.